Clinical Implications of iNOS Levels in Triple-Negative Breast Cancer Responding to Neoadjuvant Chemotherapy-Reference-Cited by-同舟云学术

Clinical Implications of iNOS Levels in Triple-Negative Breast Cancer Responding to Neoadjuvant Chemotherapy

Published:2015-07-21 Issue:7 Volume:10 Page:e0130286
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Jin Zining,Wang Wenqian,Jiang Nan,Zhang Lei,Li Yiming,Xu Xiaoyin,Cai Shouliang,Wei Liang,Liu Xuhong,Chen Guanglei,Zhou Yizhen,Liu Cheng,Li Zhan,Jin Feng,Chen Bo

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference26 articles.

1. Triple negative breast cancers express receptors for LHRH and are potential therapeutic targets for cytotoxic LHRH-analogs, AEZS 108 and AEZS 125;S Seitz;BMC Cancer,2014

2. ‘Triple negative’ breast cancer: a new area for phase III breast cancer clinical trials;LS Kilburn;Clin Oncol (R Coll Radiol),2008

3. Hallmarks of 'BRCAness' in sporadic cancers;N Turner;Nat Rev Cancer,2004

4. The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin;A Bhattacharyya;J Biol Chem,2000

5. Homology-directed DNA repair, mitomycin-C resistance, and chromosome stability is restored with correction of a Brca1mutation;ME Moynahan;Cancer Res,2001

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. βhCG mediates immune suppression through upregulation of CD11b⁺Gr1⁺ myeloid derived suppressor cells, CD206⁺M2 macrophages, and CD4⁺FOXP3⁺ regulatory T‐cells in BRCA1 deficient breast cancers;Immunology;2023-06-20

2. Targeted Therapy and Mechanisms of Drug Resistance in Breast Cancer;Cancers;2023-02-19

3. Targeting dimethylarginine dimethylaminohydrolase 1 to suppress vasculogenic mimicry in breast cancer: Current evidence and future directions;Nitric Oxide in Health and Disease;2023

4. Protein nitration induced by Hemin/NO: A complementary mechanism through the catalytic functions of hemin and NO-scavenging;Nitric Oxide;2022-07

5. A phase 1/2 clinical trial of the nitric oxide synthase inhibitor L-NMMA and taxane for treating chemoresistant triple-negative breast cancer;Science Translational Medicine;2021-12-15